Medicilon appoints Dr. Liu Jian as President of Drug Discovery Division

2023-07-12 16:49:41

BOSTON, April 20 /PRNewswire/ — Medicilon, a leading one-stop pharmaceutical CRO for preclinical R&D services, recently appointed Dr. Liu Jian appointed President of Drug Discovery Division. Medicilon recognizes the importance of drug discovery as the cornerstone of new drug innovation. With its expertise in modern synthetic chemistry, Medicilon excels in several cutting-edge areas of pharmaceutical research, including chiral drugs, glycochemistry, antibodies and antibody-drug conjugates (ADCs), nucleoside/nucleotide drugs and oligonucleotide drugs (such as RNAi) . In addition, Medicilon has made significant advances in PROTAC technology and expanded its BSL-2 laboratory facility.

With the growing pharmaceutical industry and widespread adoption of artificial intelligence, the market potential for drug discovery is huge. The recording of dr. Liu Jian, an experienced pharmaceutical research scientist, will enable the Medicilon Drug Discovery Division to revolutionize the drug discovery model and bring new ideas to drug discovery.

dr Liu Jian earned his Ph.D. in computational chemistry and organic chemistry from the University of California, Los Angeles (UCLA), followed by postdoctoral research at the University of California, Irvine and the University of Pennsylvania. In 2018 dr. Liu Jian President of the Sino-American Pharmaceutical Professionals Association (SAPA) and is currently Chairman of the Board of SAPA. In 2019, he was recognized as an “Outstanding 50 Asian American in Business” by the Asian-American Business Development Center in New York and was voted one of the 12 Most Influential Chinese American Citizens in New Jersey.

With more than 20 years of experience in the development of innovative medicines, Dr. Liu Jian led the team to develop 10 preclinical candidates (PCCs) that have entered Phase I, II and III clinical trials. He has more than 72 patents pending and 21 patents have been granted. dr Liu Jian also has profound academic achievements: he has published a total of 47 articles in international journals and served as a reviewer for several international journals.

dr Liu Jian entered the industry in 2001 and has been with Merck for almost 20 years. He led the research and development of novel small molecule drugs for various diseases including osteoporosis, obesity, diabetes, cardiovascular diseases, cancer, immune diseases, antiviral and antibacterial diseases and pain. Over the course of his career, he rose from Senior Research Chemist to Principal Scientist and External Discovery Chemistry Lead and received the Merck Excellence Award four times. He later served as CSO and Operations Director at Jiangsu Hengrui Pharmaceutical USA Drug Discovery Center (EBI) and led the development of new drugs for cancer, immune disorders, osteoarthritis and neurodegenerative diseases.Most recently, he has been CEO of Silexon AI, responsible for building the company’s artificial intelligence platform and driving innovative drug discovery.

dr Liu Jian expressed that he is honored to be part of Medicilon as President of Drug Discovery Division. Medicilon is known for building a comprehensive preclinical research and development platform in China, which has been cultivated for 19 years. It has prioritized global cutting-edge technologies and promoted technological innovation. In the future, Dr. Liu lead the Drug Discovery Division in the efficient and high-quality development of new drugs. This includes the establishment and expansion of various technical platforms for research into innovative drugs such as AIDD and structural biology, peptide and cyclic peptide development, synthetic biology and nuclear drug development. By realizing the Medicilon experiment with one-stop service from target research recommendation to IND application, we can promote innovative drug discovery.

dr Chen Chunlin, the Founder and CEO of Medicilon, said: “We welcome Dr. Liu Jian to Medicilon. We believe that his extensive academic background, outstanding leadership skills and rich R&D experience will bring Medicilon a more professional and innovative technology for the drug development and advanced industry knowledge and strategic guidance that will be critical to Medicilon’s next stage of development.

About Medicilon:

Medicilon was founded in 2004. It is a leading CRO specializing in comprehensive preclinical research and development services in the field of biomedicine. The company has established a comprehensive service and technology platform that includes drug synthesis, drug activity screening, structural biology, CMC, pharmacodynamic assessment, pharmacokinetics and toxicological safety assessment. On November 5, 2019, Medicilon was officially listed on the Science and Technology Innovation Board, becoming the first pharmaceutical CRO company to be listed on this board (Promotion Code: 688202.SH).

You can find more information on:

Photo –

View original content: